Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-10
2006-10-10
Siew, Jeffrey (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S159000, C562S475000, C562S477000
Reexamination Certificate
active
07119068
ABSTRACT:
Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity, e.g. stablized TAFIa, to ameliorate one or more adverse side effects of the therapeutic. Compounds identified by the methods of the invention are also provided.
REFERENCES:
patent: 2003/0035795 (2003-02-01), Gardell et al.
patent: WO 03/061653 (2003-07-01), None
Itami et al. (J. Org. Chem 1998, 63.6466-6471).
American Society of Hematology, Novel Fibrinolytic Action Of Aspirin Identified, Dec. 6-10, 2002, Philadelphia, PA.
An Seong Soo A.
Greenfield Robert S.
Slemon Clarke
Trifonov Latchezar
Vaugeois Jean
American Diagnostica Inc.
Fetterolf Brandon
Frommer & Lawrence & Haug LLP
Kuzmich Sandra
Quebepharma Recherche, Inc.
LandOfFree
Methods of screening for compounds that modulate TAFIa... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of screening for compounds that modulate TAFIa..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of screening for compounds that modulate TAFIa... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655695